3-[(E)-2-(3-chlorophenyl)ethenyl]-2-[6-(2H-tetrazol-5-yl)hexyl]cyclopentan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(E)-2-(3-chlorophenyl)ethenyl]-2-[6-(2H-tetrazol-5-yl)hexyl]cyclopentan-1-one
• 化学式: C₂₀H₂₅ClN₄O
• 分子量: 372.9
• InChiKey: TTXPKWYWEGVEHO-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PROSTAGLANDIN AGONISTS
  申请人：——

  公开号：US20030008895A1

  公开（公告）日：2003-01-09

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  这项发明涉及前列腺素激动剂，使用这种前列腺素激动剂的方法，含有这种前列腺素激动剂的药物组合物以及含有这种前列腺素激动剂的工具包。前列腺素激动剂对治疗包括骨质疏松在内的骨骼疾病是有用的。
• Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
  申请人：——

  公开号：US20030166631A1

  公开（公告）日：2003-09-04

  This invention is directed to pharmaceutical compositions and methods comprising prostglandin agonists, specifically EP 2 receptor selective agonists, which are useful to enhance bone repair and healing and restore or augment bone mass in vertebrates, particularly mammals. The EP 2 receptor selective agonists of the present invention are effective in the treatment of conditions such as those in which the patient has delayed or non-union fracture, bone defect, spinal fusion, bone in-growth, cranial facial reconstruction or bone sites at risk for fracture.

  本发明涉及制药组合物和方法，包括前列腺素激动剂，特别是EP2受体选择性激动剂，这些激动剂对于增强脊椎动物（特别是哺乳动物）的骨修复和愈合以及恢复或增加骨量是有用的。本发明的EP2受体选择性激动剂对于治疗患有延迟或非联合骨折、骨缺陷、脊柱融合、骨内生长、颅面重建或易于骨折的骨部位的病情是有效的。
• Treatment of osteoporsis with EP2/EP4 receptor selective agonists
  申请人：——

  公开号：US20010056060A1

  公开（公告）日：2001-12-27

  This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP 2 receptor selective agonists and EP 4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP 2 receptor and the EP 4 receptor.

  本发明涉及使用前列腺素激动剂的方法和制药组合物，其有助于预防骨质流失，恢复或增加骨量，并增强骨愈合，包括治疗低骨量症状，如骨质疏松症和/或脊椎动物中的骨缺陷，特别是哺乳动物，包括人类。本发明具体涉及包含EP2受体选择性激动剂和EP4受体选择性激动剂的方法和制药组合物，以及包含同时是EP2受体和EP4受体激动剂的药物。
• Use of prostaglandin agonists to treat erectile dysfunction or impotence
  申请人：Pfizer Products Inc.

  公开号：EP1108426A2

  公开（公告）日：2001-06-20

  The present invention relates to methods of treating impotence or erectile dysfunction which comprise administering to a patient in need of such treatment an impotence or erectile dysfunction treating amount of a prostaglandin receptor agonist.

  本发明涉及治疗阳痿或勃起功能障碍的方法，包括向需要治疗的患者施用治疗阳痿或勃起功能障碍的前列腺素受体激动剂。
• Treatment of osteoporosis with EP2/EP4 receptor selective agonists
  申请人：Pfizer Products Inc.

  公开号：EP1121939A2

  公开（公告）日：2001-08-08

  This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are useful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans, This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP2 receptor selective agonist and EP4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP2 receptor and the EP4 receptor.

  本发明涉及包含前列腺素激动剂的方法和药物组合物，前列腺素激动剂可用于防止骨质流失、恢复或增强骨量以及促进骨愈合，包括治疗脊椎动物的低骨量病症，如骨质疏松症和/或骨缺损、本发明特别涉及由 EP2 受体选择性激动剂和 EP4 受体选择性激动剂组合而成的方法和药物组合物，以及由同时为 EP2 受体和 EP4 受体激动剂的制剂组成的方法和药物组合物。